Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Blinatumomab in Adult Patients With CD19-Positive MPAL
NCT07222579Phase 2Recruiting
- Sponsor
- West Virginia University
- Start
- Jan 2026
- Primary completion
- Aug 2029
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in mixed phenotype acute leukemia (MPAL), sponsored by West Virginia University. Started Jan 2026; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT07222579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222579.